Publications

June 2024 (Revised December 2024)
Case

Lana Ghanem: Pushing the Boundaries of Health Care Through Venture Capital

By: Joshua D. Margolis and Ahmed Dahawy

Lana Ghanem, managing director of Hikma Ventures, the corporate venture arm of larger pharmaceutical group Hikma, is considering how to grow the venture arm as well as progress her own career. Over the past few years Hikma's executive team had been pressuring the... View Details

Keywords: Business Divisions; Corporate Entrepreneurship; Investment; Corporate Governance; Health Care and Treatment; Leadership Development; Business or Company Management; Growth and Development Strategy; Business Strategy; Venture Capital; Personal Development and Career; Pharmaceutical Industry; Pharmaceutical Industry; Jordan

February 2010 (Revised September 2011)
Case

Roche's Acquisition of Genentech

By: Carliss Y. Baldwin, Bo Becker and Vincent Marie Dessain

Franz Humer, CEO of the Roche Group, must decide whether to mount a hostile tender offer for the publicly-owned shares of Roche's biotechnology subsidiary, Genentech. The case provides opportunities to analyze Roche's strategy with respect to Genentech, the pros and... View Details

Keywords: Mergers and Acquisitions; Business Subsidiaries; Negotiation Offer; Organizational Culture; Corporate Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Switzerland

January 2009
Case

When Supply is of Public Interest: Roche & Tamiflu

The case focuses on the challenges of Roche maintaining a supply network for a global influenza pandemic response initiative based on its antiviral drug Tamiflu. The Roche group is a 40 billion CHF company consisting of a pharmaceutical division and a diagnostic... View Details

Keywords: Global Strategy; Health Pandemics; Distribution; Logistics; Production; Supply Chain Management; Performance Capacity; Pharmaceutical Industry

September–October 2020
Article

Social-Impact Efforts That Create Real Value

By: George Serafeim

Until the mid-2010s few investors paid attention to environmental, social, and governance (ESG) data—information about companies’ carbon footprints, labor policies, board makeup, and so forth. Today the data is widely used by investors. How can organizations create... View Details

Find at Harvard

Read Now

31 Jan 2007
Working Paper Summaries

Behavioral Decision Research, Legislation, and Society: Three Cases

Keywords: by Max H. Bazerman

October 2021 (Revised October 2022)
Case

The Opioid Settlement and Controversy Over CEO Pay at AmerisourceBergen

By: Suraj Srinivasan and Li-Kuan Ni

In 2020, AmerisourceBergen Corporation, a Fortune 50 company in the drug distribution industry, agreed to settle thousands of lawsuits filed nationwide against the company for its opioid distribution practices that critics alleged had contributed to the nationwide... View Details

01 Aug 2023
Cold Call Podcast

Can Business Transform Primary Health Care Across Africa?

Keywords: Re: Regina E. Herzlinger; Pharmaceutical; Pharmaceutical

15 Jan 2008
First Look

First Look: January 15, 2008

industry research to inform investment decisions. Provides detailed information about the recommended resources available for this type of research, focusing primarily on what is available from Harvard Business School's Baker Library. Focusing on how View Details

Keywords: Martha Lagace

14 Aug 2007
First Look

First Look: August 14, 2007

managing a master limited partnership with over $35 billion in infrastructure assets. In the summer of 2006, Richard Kinder, the founder and chairman of Kinder Morgan, led a consortium of buyers to take the company private. The... View Details

Keywords: Martha Lagace

June 2004 (Revised June 2006)
Supplement

Vertex Pharmaceuticals: R&D Portfolio Management (A)

By: Gary P. Pisano, Lee Fleming and Eli Strick

Vertex Pharmaceuticals, Inc., a drug discovery company that recently decided to pursue a vertically integrated business model, chose to build up its clinical development and commercial capabilities and infrastructure. For the first time in its history, Vertex will... View Details

Keywords: Research and Development; Investment Portfolio; Pharmaceutical Industry

05 Sep 2023
Book

Failing Well: How Your ‘Intelligent Failure’ Unlocks Your Full Potential

recessionary headwinds, the real innovation that can come out of learning from intelligent failures may be what companies most need today. As Edmondson put it, “It’s natural to hunker down and imply that failure is to be avoided in tough... View Details

Keywords: by Michael Blanding

February 2024
Case

Compass Pathways: Pioneering Psychedelic Treatment

By: Tiona Zuzul, Kisha Lashley and Gamze Yucaoglu

This case follows Compass Pathways, a pioneering company developing treatment for depression based on psilocybin, the compound found in ‘magic mushrooms.’ Psilocybin was a federally illegal substance in the U.S., and a “Schedule I” drug, defined as a drug “with no... View Details

Keywords: Commercialization; Corporate Strategy; Competitive Strategy; Product Launch; Health Testing and Trials; Research and Development; Laws and Statutes; Pharmaceutical Industry; Europe; United States; United Kingdom

15 May 2007
First Look

First Look: May 15, 2007

Purchase this note: http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=907412 HDFC (A) Harvard Business School Case 301-093 The top management team at India's leading home finance company must decide how to deal with the... View Details

Keywords: Martha Lagace

21 Apr 2009
First Look

First Look: April 21, 2009

Working PapersHow Firms Respond to Being Rated (revised) Authors:Aaron K. Chatterji and Michael W. Toffel Abstract While many rating systems seek to help buyers overcome information asymmetries when making purchasing decisions, we investigate how these ratings also... View Details

Keywords: Martha Lagace

April 2009
Case

Merck: Managing Vioxx (A)

By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred

This two-class case series allows students to stand in the shoes of CEO Ray Gilmartin during the unfolding stages of a reputational crisis. Merck's mission statement claims to "put patients first," but the company is widely criticized for putting profit before patient... View Details

Keywords: Ethics; Crisis Management; Reputation; Decision Choices and Conditions; Customers; Business or Company Management; Cost vs Benefits; Corporate Accountability; Business and Shareholder Relations; Business and Stakeholder Relations; Customer Focus and Relationships; Pharmaceutical Industry

December 2019
Case

The Business of Pain: Johnson & Johnson and the Promise of Opioids

By: Erik Snowberg, Trevor Fetter and Amy W. Schulman

This case is designed to provide an engrossing overview of stakeholder capitalism through a vigorous discussion of the conflicts that can arise when trying to serve multiple stakeholders. In 2007, Johnson & Johnson’s (J&J) subsidiary Janssen has to decide whether or... View Details

Keywords: Opioids; Addiction; Stakeholder Capitalism; Business and Stakeholder Relations; Product Launch; Decision Making; Ethics; Social Issues; Pharmaceutical Industry

25 Jul 2023
Research & Ideas

Could a Business Model Help Big Pharma Save Lives and Profit?

cross-sector and cross-border partnerships needed to execute the model. Adding new information about how pharmaceutical companies handle global public health challenges. Jessica Martinez, a former Big Pharma... View Details

Keywords: by Esther Schrader; Pharmaceutical; Pharmaceutical

April 2023
Case

Elliott Management: Capital Allocation in Biopharma

By: Amitabh Chandra, Paul Clancy and Lauren Gunasti

The case explores the intersection of capital allocation and shareholder activism in the biopharmaceutical industry. As many biopharma companies face looming patent expirations for key medicines, the case asks the question of whether investing in R&D and M&A is an... View Details

Keywords: Finance; Strategy; Capital Allocation; Biopharmaceutical Industry; Shareholder Activism; Investment Activism; Resource Allocation; Research and Development; Business and Shareholder Relations; Corporate Strategy; Pharmaceutical Industry

June 1998
Supplement

MBA Integrative Exercise: General Management, April 1998

By: Carin-Isabel Knoop

Drummond Paris, Regional Pharma Head, Asia/Pacific Novartis AG, discusses the company situation in Indonesia: joint ventures, budget, keeping track, and the prognosis for the future. View Details

Keywords: Business or Company Management; Joint Ventures; Forecasting and Prediction; Pharmaceutical Industry; Indonesia